◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksG › GALD

GALDERMA GROUP N (GALD) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-16

GALDERMA GROUP N (GALD) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Zug, Switzerland with about 7,676 employees. Its market capitalization is roughly $40 billion. In the fiscal year ended 2025-12-31, GALD reported $5.2B in revenue and $613M in net income.

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology.

Interactive charts & full statements →

GALD Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$5.2B$4.4B$4.1B$3.8B
Gross Profit$3.6B$3.1B$2.9B$2.6B
Operating Income (EBIT)$876M$678M$611M$406M
Net Income$613M$231M($57M)($98M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GALD Free Cash Flow History

Cash flow2025-12-312024-12-312023-12-312022-12-312021-12-31
Dividends Paid($41M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GALD Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-31
Total Assets$13.4B$12.6B$12.5B
Total Liabilities$5.2B$4.8B$7.1B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GALD viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← GAINAll “G” companiesGALE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.